Publications by authors named "Christopher F Massey"

Article Synopsis
  • Radiopharmaceutical therapies (RPT) trigger a type I interferon (IFN1) response in tumor cells, with the response varying based on the type of isotope used.
  • In experiments with murine tumor models, the timing and intensity of the IFN1 response were linked to the isotope's half-life and energy transfer properties.
  • Combining Ac-NM600 with immune checkpoint inhibitors enhanced survival in wild-type tumors, suggesting that the effectiveness of RPT is influenced by the radioisotope and relies on STING pathways for immune response enhancement.
View Article and Find Full Text PDF

Neuroendocrine carcinomas, such as neuroendocrine prostate cancer and small-cell lung cancer, commonly have a poor prognosis and limited therapeutic options. We report that ubiquitin carboxy-terminal hydrolase L1 (UCHL1), a deubiquitinating enzyme, is elevated in tissues and plasma from patients with neuroendocrine carcinomas. Loss of UCHL1 decreases tumor growth and inhibits metastasis of these malignancies.

View Article and Find Full Text PDF

Purpose: The lack of effective molecular biomarkers to monitor idiopathic pulmonary fibrosis (IPF) activity or treatment response remains an unmet clinical need. Herein, we determined the utility of fibroblast activation protein inhibitor for positron emission tomography (FAPI PET) imaging in a mouse model of pulmonary fibrosis.

Methods: Pulmonary fibrosis was induced by intratracheal administration of bleomycin (1 U/kg) while intratracheal saline was administered to control mice.

View Article and Find Full Text PDF

There is a clinically unmet need for effective treatments for triple-negative breast cancer (TNBC), as it remains the most aggressive subtype of breast cancer. Herein, we demonstrate a promising strategy using a tumor-targeting alkylphosphocholine (NM600) for targeted radionuclide therapy of TNBC. NM600 was radiolabeled with Y for PET imaging and Lu for targeted radionuclide therapy.

View Article and Find Full Text PDF

Finding improved therapeutic strategies against T-cell Non-Hodgkin's Lymphoma (NHL) remains an unmet clinical need. We implemented a theranostic approach employing a tumor-targeting alkylphosphocholine (NM600) radiolabeled with Y for positron emission tomography (PET) imaging and Y for targeted radionuclide therapy (TRT) of T-cell NHL. PET imaging and biodistribution performed in mouse models of T-cell NHL showed in vivo selective tumor uptake and retention of Y-NM600.

View Article and Find Full Text PDF